Literature DB >> 8289359

Adenovirus type 40 and 41 growth in vitro: host range diversity reflected by differences in patterns of DNA replication.

C T Tiemessen1, A H Kidd.   

Abstract

Subgroup F adenoviruses adapt poorly to cell culture, but the reasons for their fastidious nature are as yet ill defined. In an attempt to gain an overview of the differences in replication between adenovirus type 2 (Ad2) and representative strains of Ad40 and Ad41, cell lines which show different degrees of permissiveness to Ad40 and Ad41 were infected and examined with respect to three key functions in the Ad2 life cycle: host protein shutoff, DNA synthesis, and late antigen synthesis. The complexity of growth patterns exhibited by the subgroup F adenoviruses suggests that defectiveness is a multifactorial phenomenon not easily explainable by a single aberrant function. Furthermore, results suggest that there may be replicative defects in subgroup F adenoviruses which are not shared by both serotypes or by all strains.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8289359      PMCID: PMC236569          DOI: 10.1128/JVI.68.2.1239-1244.1994

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

1.  Differential growth of human enteric adenovirus 41 (TAK) in continuous cell lines.

Authors:  D Pieniazek; N J Pieniazek; D Macejak; J Coward; M Rayfield; R B Luftig
Journal:  Virology       Date:  1990-01       Impact factor: 3.616

2.  Selection of nonfastidious adenovirus species in 293 cells inoculated with stool specimens containing adenovirus 40.

Authors:  M Brown
Journal:  J Clin Microbiol       Date:  1985-08       Impact factor: 5.948

3.  Characterization of rotaviruses and subgroup F adenoviruses from acute summer gastroenteritis in South Africa.

Authors:  A H Kidd; A Rosenblatt; T G Besselaar; M J Erasmus; C T Tiemessen; F E Berkowitz; B D Schoub
Journal:  J Med Virol       Date:  1986-02       Impact factor: 2.327

4.  Characterization of adenovirus type 40 E1 region.

Authors:  M Ishino; Y Ohashi; T Emoto; Y Sawada; K Fujinaga
Journal:  Virology       Date:  1988-07       Impact factor: 3.616

5.  Comparison of enteric adenovirus infection in various human cell lines.

Authors:  D J Witt; E B Bousquet
Journal:  J Virol Methods       Date:  1988-08       Impact factor: 2.014

6.  Transcriptional activation by the E1A regions of adenovirus types 40 and 41.

Authors:  A E van Loon; P Gilardi; M Perricaudet; T H Rozijn; J S Sussenbach
Journal:  Virology       Date:  1987-09       Impact factor: 3.616

7.  Helper function of adenovirus 2 for adenovirus 41 antigen synthesis in semi-permissive and non-permissive cells.

Authors:  C T Tiemessen; A H Kidd
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

8.  Characterization of fastidious adenovirus types 40 and 41 by DNA restriction enzyme analysis and by neutralizing monoclonal antibodies.

Authors:  H G van der Avoort; A G Wermenbol; T P Zomerdijk; J A Kleijne; J A van Asten; P Jensma; A D Osterhaus; A H Kidd; J C de Jong
Journal:  Virus Res       Date:  1989-02       Impact factor: 3.303

9.  Complementation of enteric adenovirus type 40 for lytic growth in tissue culture by E1B 55K function of adenovirus types 5 and 12.

Authors:  V Mautner; N Mackay; V Steinthorsdottir
Journal:  Virology       Date:  1989-08       Impact factor: 3.616

10.  Two new serotypes of enteric adenovirus causing infantile diarrhoea.

Authors:  I Uhnoo; G Wadell; L Svensson; M Johansson
Journal:  Dev Biol Stand       Date:  1983
View more
  10 in total

1.  Effect of host cells on low- and medium-pressure UV inactivation of adenoviruses.

Authors:  Huiling Guo; Xiaona Chu; Jiangyong Hu
Journal:  Appl Environ Microbiol       Date:  2010-09-17       Impact factor: 4.792

2.  Adenovirus Infection of Human Enteroids Reveals Interferon Sensitivity and Preferential Infection of Goblet Cells.

Authors:  Mayumi K Holly; Jason G Smith
Journal:  J Virol       Date:  2018-04-13       Impact factor: 5.103

3.  Intravenous genetic mesothelin vaccine based on human adenovirus 40 inhibits growth and metastasis of pancreatic cancer.

Authors:  Satoshi Yamasaki; Yoshiaki Miura; Julia Davydova; Selwyn M Vickers; Masato Yamamoto
Journal:  Int J Cancer       Date:  2012-12-21       Impact factor: 7.396

4.  A single intraduodenal administration of human adenovirus 40 vaccine effectively prevents anaphylactic shock.

Authors:  Satoshi Yamasaki; Yoshiaki Miura; Julia Davydova; Selwyn M Vickers; Masato Yamamoto
Journal:  Clin Vaccine Immunol       Date:  2013-07-24

5.  Pseudopackaging of adenovirus type 5 genomes into capsids containing the hexon proteins of adenovirus serotypes B, D, or E.

Authors:  P Ostapchuk; P Hearing
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

6.  Development of a method for effective amplification of human adenovirus 40.

Authors:  Satoshi Yamasaki; Yoshiaki Miura; Eric Brown; Julia Davydova; Masato Yamamoto
Journal:  Arch Virol       Date:  2010-05-21       Impact factor: 2.574

7.  Species D human adenovirus type 9 exhibits better virus-spread ability for antitumor efficacy among alternative serotypes.

Authors:  Junji Uchino; David T Curiel; Hideyo Ugai
Journal:  PLoS One       Date:  2014-02-04       Impact factor: 3.240

Review 8.  Targeting the Viral Polymerase of Diarrhea-Causing Viruses as a Strategy to Develop a Single Broad-Spectrum Antiviral Therapy.

Authors:  Marcella Bassetto; Jana Van Dycke; Johan Neyts; Andrea Brancale; Joana Rocha-Pereira
Journal:  Viruses       Date:  2019-02-20       Impact factor: 5.048

9.  Efficient amplification of chimeric adenovirus 5/40S vectors carrying the short fiber protein of Ad40 in suspension cell cultures.

Authors:  Marta Miralles; María Mercedes Segura; Meritxell Puig; Assumpció Bosch; Miguel Chillon
Journal:  PLoS One       Date:  2012-07-31       Impact factor: 3.240

10.  Intracellular Sequestration of the NKG2D Ligand MIC B by Species F Adenovirus.

Authors:  Edson R A Oliveira; Lenong Li; Marlene Bouvier
Journal:  Viruses       Date:  2021-07-01       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.